<!– Name:DistributionId Value:8740511 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:9aeab6e8-3252-4415-8292-416d46cfd6ad –>
New York, USA, Feb. 01, 2023 (GLOBE NEWSWIRE) — Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 28+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
RRMS is the most common subtype (approximately 87%), which is characterized by unpredictable acute attacks followed by periods of remission. The growing number of patients would raise the market and demand for treatments that may cure the sickness, motivating various firms to spend on studies, research, and development in order to give better treatment alternatives.Significant innovations in the treatment of patients with multiple sclerosis (MS) have primarily addressed the frequency of flare-ups in relapsing-remitting MS (RRMS). With the evolution of technology, there has been good success in MS research, particularly in the creation of novel and diverse treatments and therapies in the clinical trial phases, and some of them are in the final trial phases and might be market-ready.
DelveInsight’s ‘Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline relapsing-remitting multiple sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the relapsing-remitting multiple sclerosis pipeline domain.
Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report
- DelveInsight’s relapsing-remitting multiple sclerosis pipeline report depicts a robust space with 28+ active players working to develop 28+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment.
- Key relapsing-remitting multiple sclerosis companies such as Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others are evaluating new drugs for relapsing-remitting multiple sclerosis to improve the treatment landscape.
- Promising relapsing-remitting multiple sclerosis pipeline therapies in various stages of development include Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.
- In March 2022, Pipeline Therapeutics is set to commence the Phase Ib/IIa clinical trial of its lead programme, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients. The move comes after the company obtained clearance for its investigational new drug application from the US Food and Drug Administration (FDA) to launch the trial. An oral, selective muscarinic M1 receptor antagonist, PIPE-307, is being developed for restoring myelin to treat MS.
- In July 2021, InnoCare received $125 million upfront in return for sharing rights to orelabrutinib, an orally-active BTK drug that can cross the blood-brain barrier and penetrate the central nervous system. It is currently in a phase 2 trial for relapsing-remitting multiple sclerosis (RRMS). The deal was back-ended with up to $812.5 million in milestone payments if the drug reaches development, regulatory and commercial milestones, and royalties on any future sales.
Request a sample and discover the recent advances in relapsing-remitting multiple sclerosis treatment drugs @ Relapsing-Remitting Multiple Sclerosis Pipeline Report
The relapsing-remitting multiple sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage relapsing-remitting multiple sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the relapsing-remitting multiple sclerosis clinical trial landscape.
Relapsing-Remitting Multiple Sclerosis Overview
Multiple sclerosis is the most common neurological disorder in young adults, with symptoms typically appearing between the ages of 20 and 40. Multiple sclerosis attacks the central nervous system’s axons, which are protected by myelin, also known as white matter. Relapsing-remitting multiple sclerosis is the most common type, accounting for approximately 85% of all multiple sclerosis patients. It is distinguished by relapses (or exacerbations) of symptoms followed by periods of remission, during which multiple sclerosis symptoms improve or disappear.
There are several unusual and rare types of multiple sclerosis. Some people with relapsing-remitting MS experience various multiple sclerosis symptoms that appear to be linked to specific triggers. Exacerbations (also known as recurrences, relapses, or seizures) are acute flare-ups of multiple sclerosis symptoms or the appearance of new symptoms that last for at least 24 h.
Find out more about relapsing-remitting multiple sclerosis treatment drugs @ Drugs for Relapsing-Remitting Multiple Sclerosis Treatment
A snapshot of the Relapsing-Remitting Multiple Sclerosis Pipeline Drugs mentioned in the report:
|IMU-838||Immunic||Phase III||Dihydroorotate dehydrogenase inhibitors||Oral|
|Fenebrutinib||Roche||Phase III||Agammaglobulinaemia tyrosine kinase inhibitors||Oral|
|Divozilimab||Biocad||Phase III||CD20 antigen inhibitors||Intravenous|
|Vafidemstat||Oryzon Genomics||Phase II||Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors||Oral|
|Temelimab||GeNeuro SA||Phase II||Toll-like receptor 4 antagonists||Intravenous|
|Elezanumab||AbbVie||Phase II||RGMA protein inhibitors||Intravenous|
Learn more about the emerging Relapsing-Remitting Multiple Sclerosis pipeline therapies @ Relapsing-Remitting Multiple Sclerosis Clinical Trials
Relapsing-Remitting Multiple Sclerosis Therapeutics Assessment
The relapsing-remitting multiple sclerosis pipeline report proffers an integral view of relapsing-remitting multiple sclerosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intravenous, Intradermal, Oral, Subcutaneous, Intramuscular
- Therapeutics Assessment By Molecule Type: Small Molecule, Gene Therapy, Peptide, Immunotherapy, Cell Therapy
- Therapeutics Assessment By Mechanism of Action: Dihydroorotate dehydrogenase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Lysine specific demethylase 1 inhibitors, Monoamine oxidase B inhibitors, Toll-like receptor 4 antagonists, RGMA protein inhibitors, CD20 antigen inhibitors
- Key Relapsing-Remitting Multiple Sclerosis Companies: TG Therapeutics, Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others
- Key Relapsing-Remitting Multiple Sclerosis Pipeline Therapies: Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.
Dive deep into rich insights for new drugs for relapsing-remitting multiple sclerosis treatment; visit @ Relapsing-Remitting Multiple Sclerosis Medications
Table of Contents
|1.||Relapsing-Remitting Multiple Sclerosis Pipeline Report Introduction|
|2.||Relapsing-Remitting Multiple Sclerosis Pipeline Report Executive Summary|
|3.||Relapsing-Remitting Multiple Sclerosis Pipeline: Overview|
|4.||Analytical Perspective In-depth Commercial Assessment|
|5.||Relapsing-Remitting Multiple Sclerosis Clinical Trial Therapeutics|
|6.||Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Pre-registration)|
|7.||Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Phase III)|
|8.||Relapsing-Remitting Multiple Sclerosis Pipeline: Mid Stage Products (Phase II)|
|9.||Relapsing-Remitting Multiple Sclerosis Pipeline: Early Stage Products (Phase I)|
|10.||Relapsing-Remitting Multiple Sclerosis Pipeline Therapeutics Assessment|
|11.||Inactive Products in the Relapsing-Remitting Multiple Sclerosis Pipeline|
|12.||Company-University Collaborations (Licensing/Partnering) Analysis|
|14.||Key Products in the Relapsing-Remitting Multiple Sclerosis Pipeline|
|16.||Market Drivers and Barriers|
|17.||Future Perspectives and Conclusion|
For further information on the relapsing-remitting multiple sclerosis pipeline therapeutics, reach out @ Relapsing-Remitting Multiple Sclerosis Treatment Drugs
Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.
Multiple Sclerosis Epidemiology Forecast
Multiple Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.
Relapsing Multiple Sclerosis Pipeline
Relapsing Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing multiple sclerosis companies, including ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, among others.
Chronic Progressive Multiple Sclerosis Pipeline
Chronic Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic progressive multiple sclerosis companies, including Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, among others.
Primary Progressive Multiple Sclerosis Pipeline
Primary Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary progressive multiple sclerosis companies, including Atara Biotherapeutics, AB Science, Sanofi, MediciNova, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Business Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn